PMID- 25467930
OWN - NLM
STAT- MEDLINE
DCOM- 20151026
LR  - 20190221
IS  - 1938-0690 (Electronic)
IS  - 1525-7304 (Print)
IS  - 1525-7304 (Linking)
VI  - 16
IP  - 2
DP  - 2015 Mar
TI  - ROS1 immunohistochemistry among major genotypes of non-small-cell lung cancer.
PG  - 106-11
LID - S1525-7304(14)00232-0 [pii]
LID - 10.1016/j.cllc.2014.10.003 [doi]
AB  - BACKGROUND: ROS1 gene fusions cause several cancers by constitutively activating 
      the ROS1 tyrosine kinase receptor. ROS1-targeted inhibitor therapy improves 
      survival in the approximately 1% to 2% of patients with lung adenocarcinoma with 
      ROS1 gene fusions. Although fluorescence in situ hybridization (FISH) is the 
      standard diagnostic procedure for detecting ROS1 rearrangements, we studied 
      immunohistochemistry (IHC). MATERIALS AND METHODS: ROS1 IHC was performed on a 
      selected cohort of 33 lung adenocarcinoma whole tissue specimens with alterations 
      in the EGFR (n = 5), KRAS (n = 5), ERBB2 (HER2) (n = 3), ROS1 (n = 6), ALK (n = 
      5), and RET (n = 3) genes and pan-negative (n = 6) detected by reverse 
      transcriptase-polymerase chain reaction (RT-PCR) and FISH. RESULTS: In the cohort 
      of 33 specimens, both ROS1 gene fusion using RT-PCR and high ROS1 protein 
      expression using IHC were detected in 6 specimens. Of these 6 specimens, 5 were 
      also positive by FISH for ROS1 gene rearrangements. All 27 lung cancer specimens 
      that were negative for ROS1 rearrangements by genetic testing had no to low ROS1 
      protein expression. CONCLUSION: We have optimized ROS1 IHC and scoring to provide 
      high sensitivity and specificity for detecting ROS1 gene rearrangements in whole 
      tissue. ROS1 IHC could be a practical and cost-effective method to screen for 
      ROS1 gene rearrangements.
CI  - Copyright (c) 2015 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Boyle, Theresa A
AU  - Boyle TA
AD  - Department of Medical Oncology and Pathology, University of Colorado, Aurora, CO.
FAU - Masago, Katsuhiro
AU  - Masago K
AD  - Division of Integrated Oncology, Institute of Biomedical Research and Innovation, 
      Kobe, Japan; Department of Pathology and Molecular Diagnostics, Aichi Cancer 
      Center, Nagoya, Japan.
FAU - Ellison, Kim E
AU  - Ellison KE
AD  - Department of Medical Oncology and Pathology, University of Colorado, Aurora, CO.
FAU - Yatabe, Yasushi
AU  - Yatabe Y
AD  - Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, 
      Japan.
FAU - Hirsch, Fred R
AU  - Hirsch FR
AD  - Department of Medical Oncology and Pathology, University of Colorado, Aurora, CO. 
      Electronic address: Fred.Hirsch@ucdenver.edu.
LA  - eng
GR  - P50 CA058187/CA/NCI NIH HHS/United States
GR  - 2P50CA058187-19A1/CA/NCI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20141024
PL  - United States
TA  - Clin Lung Cancer
JT  - Clinical lung cancer
JID - 100893225
RN  - 0 (Proto-Oncogene Proteins)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - EC 2.7.10.1 (ROS1 protein, human)
SB  - IM
MH  - Adenocarcinoma/*genetics
MH  - Adenocarcinoma of Lung
MH  - Carcinoma, Non-Small-Cell Lung/*genetics
MH  - *Gene Rearrangement
MH  - Genotype
MH  - Humans
MH  - Immunohistochemistry/methods
MH  - In Situ Hybridization, Fluorescence/methods
MH  - Lung Neoplasms/*genetics
MH  - Protein-Tyrosine Kinases/*genetics
MH  - Proto-Oncogene Proteins/*genetics
MH  - Reverse Transcriptase Polymerase Chain Reaction/methods
MH  - Sensitivity and Specificity
PMC - PMC4770803
MID - NIHMS758611
OTO - NOTNLM
OT  - Adenocarcinoma
OT  - Biomarker
OT  - Gene rearrangement
OT  - NSCLC
OT  - ROS1
COIS- All other authors have stated they have no conflicts to disclose.
EDAT- 2014/12/04 06:00
MHDA- 2015/10/27 06:00
PMCR- 2016/02/29
CRDT- 2014/12/04 06:00
PHST- 2014/08/20 00:00 [received]
PHST- 2014/10/14 00:00 [revised]
PHST- 2014/10/21 00:00 [accepted]
PHST- 2014/12/04 06:00 [entrez]
PHST- 2014/12/04 06:00 [pubmed]
PHST- 2015/10/27 06:00 [medline]
PHST- 2016/02/29 00:00 [pmc-release]
AID - S1525-7304(14)00232-0 [pii]
AID - 10.1016/j.cllc.2014.10.003 [doi]
PST - ppublish
SO  - Clin Lung Cancer. 2015 Mar;16(2):106-11. doi: 10.1016/j.cllc.2014.10.003. Epub 
      2014 Oct 24.